Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

• Published in: EJNMMI research Vol. 10; no. 1; p. 46
• Main Authors: Yeh, Mei-Chun, Tse, Brian W. C., Fletcher, Nicholas L., Houston, Zachary H., Lund, Maria, Volpert, Marianna, Stewart, Chelsea, Sokolowski, Kamil A., Jeet, Varinder, Thurecht, Kristofer J., Campbell, Douglas H., Walsh, Bradley J., Nelson, Colleen C., Russell, Pamela J.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 07.05.2020; Springer Nature B.V; SpringerOpen
• Subjects: Abnormalities; Accumulation; Antibodies; Apoptosis; Bearing; Body weight; Cardiac Imaging; Computed tomography; Glypican-1; Imaging; Lutetium isotopes; Medical imaging; Medicine; Medicine & Public Health; MIL-38; Miltuximab; Novel Theragnostic Drugs; Nuclear Medicine; Oncology; Organs; Original Research; Orthopedics; Positron emission; Prostate cancer; Radiology; Radionuclide therapy; Survival; Therapy; Tomography; Tumors; Xenotransplantation; Zirconium isotopes; Miltuximab; Radionuclide therapy; Glypican-1; Prostate cancer; MIL-38

Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate c...